Voloridge Investment Management LLC Buys 148,512 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Voloridge Investment Management LLC increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 325.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 194,103 shares of the medical research company's stock after acquiring an additional 148,512 shares during the period. Voloridge Investment Management LLC owned 0.11% of IQVIA worth $38,143,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the stock. Synergy Asset Management LLC bought a new position in IQVIA in the 4th quarter worth approximately $33,000. GKV Capital Management Co. Inc. bought a new position in IQVIA in the 4th quarter worth approximately $39,000. Lee Danner & Bass Inc. bought a new position in IQVIA in the 4th quarter worth approximately $44,000. Zions Bancorporation N.A. increased its position in IQVIA by 55.2% in the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock worth $47,000 after buying an additional 85 shares during the period. Finally, SBI Securities Co. Ltd. bought a new position in IQVIA in the 4th quarter worth approximately $60,000. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Price Performance

IQVIA stock traded up $4.79 on Tuesday, reaching $141.79. The company's stock had a trading volume of 349,853 shares, compared to its average volume of 1,864,931. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $252.88. The company has a market cap of $24.53 billion, a price-to-earnings ratio of 18.90, a PEG ratio of 1.99 and a beta of 1.34. The business's fifty day moving average price is $154.34 and its 200 day moving average price is $182.55.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.63 by $0.07. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The business had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. During the same quarter in the prior year, the firm posted $2.54 earnings per share. The firm's revenue for the quarter was up 2.5% compared to the same quarter last year. Equities analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently issued reports on IQV. Truist Financial lowered their price objective on IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a research report on Thursday, April 10th. Mizuho lowered their price objective on IQVIA from $210.00 to $190.00 and set an "outperform" rating on the stock in a research report on Thursday, May 15th. Stifel Nicolaus lowered their price objective on IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. HSBC cut IQVIA from a "buy" rating to a "hold" rating and lowered their price objective for the company from $260.00 to $160.00 in a research report on Friday, April 25th. Finally, JPMorgan Chase & Co. lowered their price objective on IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a research report on Monday, May 19th. Eight investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $226.32.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.